Study of First Affordable and Rapid Test for Beta Thalassemia Performs at 99% Accuracy in Diagnosing the Blood Disorder
February 05, 2024 08:00 ET
|
Hemex Health
A clinical study demonstrated high accuracy for Hemex Health's beta thalassemia test. It is the only beta thal test for point of care.
California State Treasurer, Fiona Ma, and US-India cross-border association, AllianceIndus, congratulate Hemex Health for India partnerships that led to a breakthrough test for sickle cell disease
October 17, 2023 21:00 ET
|
Hemex Health
SAN FRANCISCO and PORTLAND, Ore., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemex Health, Inc., a medical device company based in Portland, Oregon and Mumbai, India, was honored today by AllianceIndus at...
Hemex Health Awarded $3M NIH Grant to Bring Gazelle Hb Variant Test for Sickle Cell Disease to US Market
March 27, 2023 08:00 ET
|
Hemex Health
PORTLAND, Ore., March 27, 2023 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostic device company focused on expanding healthcare access to underrepresented patient populations, announced it has...
Beta Thalassemia Clinical Trials Pipeline Analysis: 22+ Companies are Working to Improve the Treatment Space | DelveInsight
January 09, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Beta Thalassemia Clinical Trials Pipeline Analysis: 22+ Companies are Working to Improve the Treatment Space | DelveInsight The prevalence of...
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
May 08, 2022 06:00 ET
|
Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
April 05, 2022 06:45 ET
|
Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
Imara Reports Full Year 2021 Financial Results and Business Highlights
March 15, 2022 07:00 ET
|
Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 05, 2022 07:00 ET
|
Imara, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 14, 2021 07:00 ET
|
Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...